Our competitors may succeed in developing, acquiring, or licensing on an exclusive basis, products that are more effective or less costly than any drug candidate that we may develop, or achieve earlier patent protection, regulatory approval, product commercialization, and market penetration than we do.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note Lead focus area. FDA orphan drug designation granted; clinical trials initiated in the US. All candidates described as in early clinical development; no phase, indication, or readout timing stated in excerpts.
VIS-101
Stage not disclosed · Active
Target VEGF-A / ANG-2
Status note Open FDA IND; named as a focus area. No target, indication, or phase stated in excerpts.
Ragistomig
Stage not disclosed · Active
Target PD-L1 / 4-1BB
Status note Open FDA IND. No target, indication, or phase stated in excerpts.
Uliledlimab
Stage not disclosed · Active
Target CD73
Status note Open FDA IND; clinical trials initiated in the US. No target, indication, or phase stated in excerpts.
Per-asset detail extracted from the 20-F filed 2026-04-07. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.